- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 21 - Expectations for Newly Developing Agents
During this segment, the panelists explore newer therapeutic agents that are now receiving a lot of attention in the healthcare market for the management of cardiovascular health, and discuss which products have the greatest potential when treating cardiometabolic events.
David Calabrese, RPh, MHP, discusses the large number of late-phase agents that are available to treat diabetes and believes that product variety allows clinicians to tailor treatment specifically to the patient.
Additionally, Kenneth L. Schaecher, MD, FACP, CPC, discusses the potential of vaccine therapy and gene therapy, which are currently being studied for the treatment of type 1 diabetes.
Yehuda Handelsman, MD, FACP, FACE, FNLA, concludes the discussion by summarizing the most promising products available to treat other cardiometabolic events such as lipid disorders and obesity.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
From Red Tape to Relief: Rewriting the Rules of Prior Authorization
June 23rd 2025Up to 257 million Americans could benefit from these prior authorization reforms that could have cross-market implications on health care plans administered through commercial insurers, Medicare Advantage, and Medicaid.
Read More
Moving Evidence From Research to Practice: Q&A With Ken Cohen, MD
June 23rd 2025In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Ken Cohen, MD, executive director of translational research at Optum Health.
Read More
